TY - JOUR
T1 - Two virulent bacteriophages targeting carbapenem-resistant Raoultella planticola
AU - Hoang, Cuong V.
AU - Fan, Jonathan
AU - Bhasin, Lauren
AU - Del Mundo, Anthony
AU - Law, Vanessa
AU - Nguyen, Dominic
AU - Ganiger, Suraj
AU - Mansour, Ashley
AU - McElheny, Christi L.
AU - Doi, Yohei
AU - Olawole, Olakunle I.
N1 - Publisher Copyright:
Copyright © 2026 Hoang, Fan, Bhasin, Del Mundo, Law, Nguyen, Ganiger, Mansour, McElheny, Doi and Olawole.
PY - 2026
Y1 - 2026
N2 - Carbapenem-resistant Raoultella planticola (CRRP) is an emerging nosocomial pathogen with limited therapeutic options. Here, we describe the comparative characterization of two novel virulent bacteriophages, Macy and Sally, both isolated from the same soil microenvironment. Macy exhibits exceptional lytic potency, with a burst size of 8,375 PFU per infected cell, narrow host specificity, and pronounced biofilm-disrupting activity likely mediated by a putative depolymerase. In contrast, Sally displays a broader host range, infecting both R. planticola and R. ornithinolytica (including a clinical CRRP isolate), while maintaining moderate lytic activity, notable acid tolerance, and substantial biofilm reduction. SNP analysis revealed that resistant isolates carried mutations in genes linked to surface polysaccharide biosynthesis and LysR-family transcriptional regulation, conferring resistance at a measurable cost to bacterial growth fitness. Genomic and phylogenomic analyses further revealed distinct evolutionary trajectories: Macy is a large (147.8 kb) member of Straboviridae Straboviridae with a mosaic genome related to Raoultella phages, whereas Sally is a compact (48.5 kb) Casjensviridae phage that is siphovirus more closely aligned with Klebsiella and Enterobacter phages. Pangenomic comparisons highlighted Macy’s strain-specific gene expansions versus Sally’s cross-genus homology, emphasizing divergent adaptation strategies. Together, these findings illustrate the complementary therapeutic potential of Macy and Sally and establish a genomic and phenotypic foundation for developing effective phage cocktails against multidrug-resistant Raoultella infections.
AB - Carbapenem-resistant Raoultella planticola (CRRP) is an emerging nosocomial pathogen with limited therapeutic options. Here, we describe the comparative characterization of two novel virulent bacteriophages, Macy and Sally, both isolated from the same soil microenvironment. Macy exhibits exceptional lytic potency, with a burst size of 8,375 PFU per infected cell, narrow host specificity, and pronounced biofilm-disrupting activity likely mediated by a putative depolymerase. In contrast, Sally displays a broader host range, infecting both R. planticola and R. ornithinolytica (including a clinical CRRP isolate), while maintaining moderate lytic activity, notable acid tolerance, and substantial biofilm reduction. SNP analysis revealed that resistant isolates carried mutations in genes linked to surface polysaccharide biosynthesis and LysR-family transcriptional regulation, conferring resistance at a measurable cost to bacterial growth fitness. Genomic and phylogenomic analyses further revealed distinct evolutionary trajectories: Macy is a large (147.8 kb) member of Straboviridae Straboviridae with a mosaic genome related to Raoultella phages, whereas Sally is a compact (48.5 kb) Casjensviridae phage that is siphovirus more closely aligned with Klebsiella and Enterobacter phages. Pangenomic comparisons highlighted Macy’s strain-specific gene expansions versus Sally’s cross-genus homology, emphasizing divergent adaptation strategies. Together, these findings illustrate the complementary therapeutic potential of Macy and Sally and establish a genomic and phenotypic foundation for developing effective phage cocktails against multidrug-resistant Raoultella infections.
KW - bacteriophage therapy
KW - carbapenem-resistant Raoultella planticola
KW - clinical strains
KW - host range
KW - multidrug-resistant pathogens
UR - https://www.scopus.com/pages/publications/105028572113
UR - https://www.scopus.com/pages/publications/105028572113#tab=citedBy
U2 - 10.3389/fmicb.2025.1726803
DO - 10.3389/fmicb.2025.1726803
M3 - Article
AN - SCOPUS:105028572113
SN - 1664-302X
VL - 16
JO - Frontiers in Microbiology
JF - Frontiers in Microbiology
M1 - 1726803
ER -